Finasteride metabolism and pharmacogenetics: New approaches to personalized prevention of prostate cancer

Future Oncology

Volumn 6, Issue 12, 2010, Pages 1897-1913

  Hulin Curtis, Sarah L ^a   Petit, Dominique ^a   Figg, W Douglas ^b   Hsing, Ann W ^b   Reichardt, Juergen Kv ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

androgen; CYP3A4; finasteride; haplotype; personalized medicine; pharmacogenetics; prostate cancer; single nucleotide polymorphism; SRD5A2; UGT1A

Indexed keywords

CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DUTASTERIDE; FINASTERIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; HYDROXYSTEROID DEHYDROGENASE; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHOGLUCURONOSYLTRANSFERASE;

ANDROGEN METABOLISM; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSFORMATION; ENDOPLASMIC RETICULUM; GENETIC VARIABILITY; HAPLOTYPE; INHERITANCE; MISSENSE MUTATION; PHARMACOGENETICS; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; 5-ALPHA REDUCTASE INHIBITORS; CYTOCHROME P-450 CYP3A; FINASTERIDE; GENETIC VARIATION; GLUCURONOSYLTRANSFERASE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 78650471532     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.149     Document Type: Review

References (133)

1. Haas GP, Sakr WA: Epidemiology of prostate cancer. CA Cancer J. Clin. 47, 273-287 (1997).
2. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD: Age and racial distibution of prostatic intraepithelial neoplasia. Eur. Urol. 30, 138-144 (1996).
3. Jänne OA, Palvimo JJ, Kallio P, Mehto M: Androgen receptor and mechanisms of androgen action. Ann. Med. 25, 83-89 (1993).
4. Andersson S, Russell DW: Structural and biochemical properties of cloned and expressed human and rat steroid 5a-reductases. Proc. Natl Acad. Sci. 87, 3640-3644 (1990).
5. Tamura K, Furihata M, Tsunoda T et al.: Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 67, 5117-5125 (2007).
6. Hsing AW, Reichardt JK, Stanczyk FZ: Hormones and prostate cancer: current perspectives and future directions. Prostate 52, 213-235 (2002).
7. Zhu YS, Imperato-McGinley JL: 5a-reductase isozymes and androgen actions in the prostate. Ann. NY Acad. Sci. 1155, 43-56 (2009).
8. Nickel JC: Comparison of clinical trials with finasteride and dutasteride. Rev. Urol. 6(Suppl. 9), S31-S39 (2004).
9. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS: Dutasteride, the dual 5a-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 58, 130-144 (2004).
10. Bruchovsky N, Lesser B, Van Doorn E, Craven S: Hormonal effects on cell proliferation in rat prostate. Vitam. Horm. 33, 61-102 (1975).
11. Thompson IM, Phyllis JG, Tangen CM et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003).
12. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS: Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64, 537-541 (2004).
13. Shahani R, Fleshner NE, Zlotta AR: Pharmacotherapy for prostate cancer: the role of hormonal treatment. Discov. Med. 7, 118-124 (2007).
14. Walsh PC: Chemoprevention of prostate cancer. N. Engl. J. Med. 362, 1237-1238 (2010).
15. Motulsky AG: Drug reaction enzymes, and biochemical genetics. J. Am. Med. Assoc. 165, 835-837 (1957).
16. Nebert DW: From genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40, 187-224 (2008).
17. Goldstein DB: The genetics of human drug response. Phil. Trans. R. Soc. B 360, 1571-1572 (2005).
18. Tate SK, Depondt C, Sisodiya SM et al.: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102, 5507-5512 (2005).
19. Goldstein DB, Tate SK, Sisodiya SM: Pharmacogenetics goes genomic. Nat. Rev. Genet. 4, 937-947 (2003).
20. Surendiran A, Pradhan SC, Adithan C: Role of pharmacogenomics in drug discovery and development. Indian J. Pharmacol. 40, 137-143 (2008).
21. Walko CM, McLeod H: Pharmacogenomic progress in individualised dosing of key drugs for cancer patients. Nat. Clin. Prac. Oncol. 6, 153-162 (2009).
22. Zhou SF, Di YM, Chan E et al.: Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 8, 738-784 (2008).
23. Makridakis NM, di Salle E, Reichardt JKV: Biochemical and pharmacogenetic dissection of human steroid 5a-reductase type II. Pharmacogenetics 10, 407-413 (2000).
24. Makridakis N, Akalu A, Reichardt JKV: Identification and characterisation of somatic steroid 5a-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 23, 7399-7405 (2004).
25. Makridakis N, Reichardt JKV: Pharmacogenetic analysis of human steroid 5a-reductase type II: comparison of finasteride and dutasteride. J. Mol. Endocrinol. 34, 617-623 (2005).
26. Chu LW, Reichardt JK, Hsing AW: Androgens and the molecular epidemiology of prostate cancer. Curr. Opin. Endocrinol. Diabetes Obes. 15, 261-270 (2008).
27. Goldstein DB, Weale ME: Linkage disequilibrium holds the key. Curr. Biol. 11, R576-R579 (2001).
28. Johnson GC, Esposito L, Barratt BJ et al.: Haplotype tagging for the identification of common disease genes. Nat. Genet. 29, 233-237 (2001).
29. Reich DE, Cargill M, Bolk M et al.: Linkage disequilibrium in the human genome. Nature 411, 199-204 (2001).
30. Gu CC, Yu K, Ketkar S, Templeton AR, Rao DC: On transferability of genome-wide tag SNPs. Genet. Epidemiol. 32, 89-97 (2008).
31. Mehrain-Shai R, Reichardt JKV: A renaissance of biochemical genetics? SNPs, haplotypes, function, and complex diseases. Mol. Gen. Metab. 83, 47-50 (2004).
32. Vineis P, Khan AE, Vlaanderen J, Vermeulen R: The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability. Environ. Health 8, 54 (2009).
33. Ma BBY, Hui EP, Mok TSK: Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol. 11, 75-84 (2010).
34. Cascorbi I: Genetic basis of toxic reactions to drugs and chemicals. Toxicol. Lett. 162, 16-28 (2006).
35. Reich DE, Lander ES: On the allelic spectrum of human disease. Trends Genet. 17, 502-510 (2001).
36. Campbell H, Manolio T: Commentary: rare alleles, modest genetic effects and the need for collaboration. Int. J. Epidemiol. 36(2), 445-448 (2007).
37. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB: Rare variants create synthetic genome-wide associations. PLoS Biol. 8, 1-12 (2010).
38. Huggins C, Steven R: The effect of castration on benign hypertrophy of the prostate in man. J. Urol. 43, 705 (1940).
39. Marks LS: 5a-reductase: history and clinical importance. Rev. Urol. 6, S11-S21 (2004).
40. Gormley GJ, Stoner E, Bruskewitz RC et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. 327, 1185-1191 (1992).
41. Kramer BS, Hagerty KL, Justman S et al.: Use of 5-a-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. J. Clin. Oncol. 27, 1502-1516 (2009).
42. Stephenson AJ, Abouassaly R, Klein EA: Chemoprevention of prostate cancer. Urol. Clin. North Am. 37, 11-21 (2010).
43. Strope SA, Andriole GL: Update on chemoprevention for prostate cancer. Curr. Opin. Urol. 20(3), 194-197 (2010).
44. Vickers AJ, Savage CJ, Lilja H: Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J. Clin. Oncol. 28, 1112-1116 (2010).
45. Reynolds T: Prostate cancer prevention trial yields positive results, but with a few cautions. J. Natl Cancer Inst. 95, 1030-1031 (2003).
46. Crawford ED, Andriole GL, Marberger M, Rittmaster RS: Reduction on the risk of prostate cancer: future directions after the prostate cancer prevention trial. Urology 75, 502-510 (2010).
47. Bull HG, Garcia-Calvo M, Andersson S et al.: Mechanism-based inhibition of human steroid 5a-reductase by finasteride: enzyme-catalyzed formation of NADP- dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. 118, 2359-2365 (1996).
48. Schloss JV: Significance of slow-binding enzyme inhibition and its relationship to reaction-intermediate analogues. Accounts Chem. Res. 21, 348-353 (1988).
49. Lavogina D, Enkvist E, Uri A: Bisubstrate inhibitors of protein kinases: from principles to practical applications. Chem. Med. Chem. 5, 23-34 (2010).
50. Faller B, Farley D, Nick H: Finasteride: a slow-binding 5a-reductase inhibitor. Biochemistry 32, 5705-5710 (1993).
51. Drury JE, Di Costanzo L, Penning TM, Christianson DW: Inhibition of human steroid 5b-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. J. Biol. Chem. 284(30), 19786-19790 (2009).
52. Wrighton SA, Stevens JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).
53. Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 360, 1155-1162 (2002).
54. Perera MA: The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin. Drug Metab. Toxicol. 6, 17-28 (2010).
55. Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH: Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab. Dispos. 23, 1126-1135 (1995).
56. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 b-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263, 424-436 (1988).
57. Sata F, Sapone A, Elizondo G et al.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48-56 (2000).
58. Smith RL, Williams RT: Implication of the conjugation of drugs and other exogenous compounds. In: Glucuronic Acid: Free and Combined: Chemistry, Biochemistry, Pharmacology and Medicine. Dutton GJ (Ed.). Academic Press, NY, USA, 58-69 (1966).
59. Wells PG, Mackenzie PI, Chowdury JR et al.: Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 32, 281-290 (2004).
60. Nagar S, Remmel RP: Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25, 1659-1672 (2006).
61. Barbier O, Belaner A: Inactivation of androgens by UDP- glucuronosyltransferases in the human prostate. Best Pract. Res. Clin. Endocrinol. Metab. 22, 259-270 (2008).
62. Ritter JK: Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 129, 171-193 (2000).
63. Guillemette C, Lévesque E, Harvey M, Bellemare J, Menard V: UGT genomic diversity: beyond gene duplication. Drug Metab. Rev. 42, 24-44 (2010).
64. Operaña TN, Tukey RH: Oligomerization of the UDP- glucuronosyltransferase 1A proteins. J. Biol. Chem. 282, 4821-4829 (2007).
65. Lundahl A, Lennernas H, Knutson L et al.: Identification of finasteride metabolites in human bile and urine by high-performance liquid chromatography/tandem mass spectrometry. Drug Metab. Dispos. 37, 2008-2017 (2009).
66. Soars MG, Burchell B, Riley RJ: In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J. Pharmacol. Exp. Ther. 301, 382-390 (2002).
67. Tukey RH, Strassburg CP: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616 (2000).
68. Lundahl A, Hedeland M, Bondesson U, Knutson L, Lennernäs H: The effect of St. Johns wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur. J. Pharm. Sci. 36, 433-443 (2009).
69. Carlin JR, Hoglund P, Eriksson LO, Christofalo P, Gregoire SL, Taylor AM: Disposition and pharmacokinetics of 14C finasteride after oral administration in humans. Drug Metab. Dispos. 20, 148-155 (1992).
70. Loftsson T, Hreinsdttir D: Determination of aqueous solubility by heating and equilibration: a technical note. AAPS PharmSciTech. 7, E1-E4 (2006).
71. Bergman E, Forsell P, Tevell A et al.: Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur. J. Pharm. Sci. 29, 205-214 (2006).
72. Persson EM, Nilsson RG, Hansson GL, Lfgren LJ, Lidbäck F, Knutson L: A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Phar. Res. 23, 742-751 (2006).
73. Ishii Y, Mukoyama H, Ohtawa M: In vivo biotransformation of finasteride in rat hepatic microsomes. Drug Metab. Dispos. 22, 79-84 (1994).
74. Liu MJ, Pollack GM: Pharmacokinetics and pharmacodynamics of valproate analogs in rats. II. Pharmacokinetics of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid. Biopharm. Drug Dispos. 14, 325-339 (1993).
75. Shipkova M, Armstrong VW, Oellerich M, Wieland E: Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 25, 1-16 (2003).
76. Makridakis NM, Ross RK, Pike MC et al.: Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354, 975-978 (1999).
77. Latil AG, Azzouzi R, Cancel GS et al.: Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92, 1130-1137 (2001).
78. Cussenot O, Azzouzi AR, Nicolaiew N et al.: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-a-reductase inhibitors. Eur. Urol. 52, 1082-1089 (2007).
79. Wang M, Bhattacharyya AK, Taylor MF, Tai HH, Collins DC: Site-directed mutagenesis studies of the NADPH-binding domain of rat steroid 5a-reductase (isozyme-1) I: analysis of aromatic and hydroxylated amino acid residues. Steroids 64, 356-362 (1999).
80. Ramos L, Chávez B, Vilchis F: Cloning and differential expression of steroid 5-a-reductase type I (SRD5A1) and type II (SRD5A2) from the Harderian glands of hamsters. Gen. Comp. Endocrinol. 166, 388-395 (2010).
81. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Delivery Rev. 54, 1271-1294 (2002).
82. Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R: Gender difference in ifosfamide metabolism by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 26, 193-200 (2001).
83. Ozdemir V, Kalowa W, Tang BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373-388 (2000).
84. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human bowel enterocytes. J. Clin. Invest. 90, 1871-1878 (1992).
85. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB: CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48, 716-727 (1999).
86. Dai D, Tang J, Rose R et al.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299, 825-831 (2001).
87. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90, 1225-1229 (1998).
88. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA: Association between a CYP3A4 genetic variant and clinical presentation in African- American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 8, 901-905 (1999).
89. Zeigler-Johnson CM, Walker AH, Mancke B et al.: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum. Hered. 54, 13-21 (2002).
90. Bangsi D, Zhou JY, Sun Y, Patel NP, Darga LL, Heilbrun LK: Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol. Oncol. 24, 21-27 (2006).
91. Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J: Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum. Mut. 27, 717-730 (2006).
92. Loukola A, Chadha M, Penn SG et al.: Comprehensive evaluation of the association between prostate cancer and genotypes/ haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur. J. Hum. Genet. 12, 321-332 (2004).
93. Keuhl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
94. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 12, 928-932 (2003).
95. Sinues B, Vicente J, Fanlo A et al.: CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther. Drug Monit. 29, 412-416 (2007).
96. Bosch TM, Doodeman VD, Smits PHM, Meijerman I, Schellens JHM, Beijnen JH: Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol. Diag. Ther. 10, 175-185 (2006).
97. Thompson EE, Kuttab-Boulos H, Yang L, Roe BA, Di Renzo A: Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J. 6, 105-114 (2006).
98. Dally H, Bartsch H, Jäger B et al.: Genotype relationships in the CYP3A locus in Canadians. Cancer Lett. 207, 95-99 (2004).
99. Strassburg CP, Kalthoff S, Ehmer U: Variability and function of family 1 uridine-5-diphosphate glucuronosyltransferases (UGT1A). Crit. Rev. Clin. Lab. Sci. 45, 485-530 (2008).
100. Wells PG, Mackenzie PI, Chowdhury JR et al.: Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 32, 281-290 (2004).
101. Gong QH, Cho JW, Huang T et al.: Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11, 357-368 (2001).
102. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP: Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39, 970-977 (2004).
103. Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y: Six novel UDP glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J. Hum. Genet. 49, 123-128 (2004).
104. Rittmaster RS, Fleshner NE, Thompson IM: Pharmacological approaches to reducing the risk of prostate cancer. Eur. Urol. 55, 1064-1107(2009).
105. Price D, Stein B, Sieber P: Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, Phase IIb clinical trial. J. Urol. 176, 965-970 (2006).
106. Lippman SM, Klein EA, Goodman PJ et al.: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J. Am. Med. Assoc. 301, 39-51 (2009).
107. Jafari S, Etminan M, Afshar K: Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can. Urol. Assoc. J. 3, 323-330 (2009).
108. Hussain T, Gupta S, Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 191, 125-135 (2003).
109. Algotar AM, Thompson PA, Ranger-Moore J et al.: Effect of aspirin, other NSAIDs, statins on PSA and PSA velocity. Prostate 70(8), 883-888 (2010).
110. Brown G, Albers JJ, Fisher LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323, 1289-1298 (1990).
111. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimes. JAMA 264, 3007-3012 (1990).
112. Jasinska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. 59, 483-499 (2007).
113. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Habel LA: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol. Drug Saf. 17, 27-36 (2008).
114. Murtola TJ, Visakorpi T, Lahtela J, Syvälä H, Tammela TLJ: Statins and prostate cancer prevention: where are we now and future directions. Nat. Clin. Pract. Urol. 5, 376-387 (2008).
115. Brookhart MA, Patrick AR, Dormuth C et al.: Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am. J. Epidemiol. 166, 348-354 (2007).
116. Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA: Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control 21, 61-68 (2010).
117. Murtola TJ, Tammela TLJ, Määttänen L et al.: Prostate cancer and PSA among statin users in the Finnish Prostate Cancer Screening Trial. Int. J. Cancer 127(7), 1650-1659 (2010).
118. Hofland J, van Weerden WM, Dits NF et al.: Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 70, 1256-1264 (2010).
119. Andriole GL, Bostwick DG, Brawley OW et al.: Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192-1202 (2010).
120. Roehrborn CG, Siami P, Barkin J et al.: The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4 year results from the CombAT study. Eur. Urol. 57, 123-131 (2010).
121. Eeles RA, Kote-Jarai Z, Al Olama AA et al.: Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 41, 1116-1121 (2009).
122. Hooker S, Hernandez W, Chen H et al.: Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and XpII in African- Americans. Prostate 70, 270-275 (2010).
123. Xu J, Kibel AS, Hu JJ et al.: Prostate cancer risk associated loci in African-Americans. Cancer Epidemiol. Biomarkers Prev. 18, 2145-2149 (2009).
124. Kote-Jarai Z, Easton DF, Stanford JL et al.: Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL constortium. Cancer Epidemiol. Biomarkers Prev. 17, 2052-2061 (2008).
125. Carson C, Rittmaster R: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61(Suppl. 4A), 2-7 (2003).
126. Cancer Research UK homepage www.cancerresearchuk.org
127. American Cancer Society: Cancer facts and figures 2010 www.cancer.org/acs/groups/content/@ epidemiologysurveilance/documents/ document/acspc-026238.pdf
128. MedlinePlus drug information for finasteride www.nlm.nih.gov/medlineplus/ druginfo/ meds/a698016.html
129. Prescribing information for Avodart® www.accessdata.fda.gov/ drugsatfda-docs/ label/2008/021319s015lbl.pdf
130. GeneCards: SRD5A1 gene information www.genecards.org/cgi-bin/carddisp. pl?gene=Srd5a1
131. GeneCards: SRD5A2 gene information www.genecards.org/cgi-bin/carddisp. pl?gene=Srd5a2
132. Finasteride: drug information provided by Lexi-Comp www.merck.com/mmpe/ lexicomp/ finasteride.html
133. National Center for Biotechnology Information single nucleotide polymorphisms database www.ncbi.nlm.nih.gov/snp